- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00911092
Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer (COL)
September 15, 2026 updated by: Centre Oscar Lambret
Study of Predictive Proteomic Factors of the Response to Exclusive Concomitant Radiochemotherapy in Oesophageal Cancer
The scope of the trial is to predict the early complete clinical response to exclusive concomitant radiochemotherapy in esophageal cancer by the study of the pre- and per- therapeutic proteomic profile.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Further informations will be provided by Centre Oscar Lambret.
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Angers, France, 49933
- Centre Paul Papin
-
Brest, France, 29200
- Centre Hospitalier Universitaire
-
Caen, France, 14046
- Centre François Baclesse
-
Lille, France, 59020
- Centre Oscar Lambret
-
Rennes, France, 35042
- Centre Eugene Marquis
-
Rouen, France, 76031
- CHU - Hopital Charles Nicolle
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Invasive esophageal carcinoma at any stage (all T, N0 or N1, M0 or M1a), histologically proven
- Treated by exclusive concomitant radiochemotherapy
- Written informed consent
Exclusion Criteria:
- Presence of a second uncontrolled cancer
- Metastatic carcinoma
- Metastatic disease, except cervical lymphnodes... (M1a)
- In situ carcinoma
- Eso-gastric junction cancer (Siewert II ou III)
- Inclusion in a clinical trial with an experimental drug during the study and until 15 weeks after the end of radiotherapy)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proteomic analysis by Protein-Chip Technology of Ciphergen and mass spectrometry
Time Frame: 15 weeks after the end of irradiation
|
15 weeks after the end of irradiation
|
|
Initial complete clinical response
Time Frame: 15 weeks after the end of irradiation
|
15 weeks after the end of irradiation
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Prolonged clinical response at one year
Time Frame: One year after the end of irradiation
|
One year after the end of irradiation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: ADENIS Antoine, MD, PhD, Centre Oscar Lambret
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2007
Primary Completion (Actual)
September 1, 2011
Study Completion (Actual)
December 1, 2011
Study Registration Dates
First Submitted
May 29, 2009
First Submitted That Met QC Criteria
May 29, 2009
First Posted (Estimated)
June 1, 2009
Study Record Updates
Last Update Posted (Actual)
September 17, 2026
Last Update Submitted That Met QC Criteria
September 15, 2026
Last Verified
September 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Esophageal Neoplasms
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Investigative Techniques
- Therapeutics
- Specimen Handling
- Clinical Laboratory Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Punctures
- Surgical Procedures, Operative
- Physical Phenomena
- Inorganic Chemicals
- Chlorine Compounds
- Nitrogen Compounds
- Pyrimidines
- Uracil
- Pyrimidinones
- Platinum Compounds
- Fluorouracil
- Cisplatin
- Radiation
- Drug Therapy
- Blood Specimen Collection
Other Study ID Numbers
- COL-0613
- 2006-A00568-43 (Other Identifier: AFSSAPS)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.